CureVac

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

CureVac Announces Voting Results of General Meeting

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

CureVac Announces Update to the Management Team

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

CureVac Announces Voting Results of General Meeting

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech